Posted by Michael Wonder on 04 May 2021
SIGA announces new drug application filing with FDA for intravenous formulation of TPOXX
4 May 2021 - Important for patients who cannot swallow oral capsules.
SIGA Technologies today announced that it has filed a new drug application with the U.S. FDA for the intravenous formulation of TPOXX.
The proposed indication, for the treatment of human smallpox disease in adults and paediatric patients weighing 13 kg or more, is the same as what was approved by the FDA in July 2018 for the oral formulation of TPOXX.
